Evidence map›Paper›PMID 36080188›Full record

ReviewMolecules (Basel, Switzerland)2022

Multivalent Pyrrolidine Iminosugars: Synthesis and Biological Relevance.

Yali Wang, Jian Xiao, Aiguo Meng, Chunyan Liu

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yali WangCollege of Pharmacy, North China University of Science and Technology, Tangshan 063000, China.
Jian XiaoCollege of Pharmacy, North China University of Science and Technology, Tangshan 063000, China.
Aiguo MengAffiliated Hospital, North China University of Science and Technology, Tangshan 063000, China.
Chunyan LiuCollege of Pharmacy, North China University of Science and Technology, Tangshan 063000, China.ORCID 0000-0001-5653-8190
North China University of Science and Technology · CN

Funding

National Science Foundation of Hebei province, China H2020209288National Science Foundation of Hebei province, China H2021209056
6 · The paper itself

Abstract

Recently, the strategy of multivalency has been widely employed to design glycosidase inhibitors, as glycomimetic clusters often induce marked enzyme inhibition relative to monovalent analogs. Polyhydroxylated pyrrolidines, one of the most studied classes of iminosugars, are an attractive moiety due to their potent and specific inhibition of glycosidases and glycosyltransferases, which are associated with many crucial biological processes. The development of multivalent pyrrolidine derivatives as glycosidase inhibitors has resulted in several promising compounds that stand out. Herein, we comprehensively summarized the different synthetic approaches to the preparation of multivalent pyrrolidine clusters, from total synthesis of divalent iminosugars to complex architectures bearing twelve pyrrolidine motifs. Enzyme inhibitory properties and multivalent effects of these synthesized iminosugars were further discussed, especially for some less studied therapeutically relevant enzymes. We envision that this comprehensive review will help extend the applications of multivalent pyrrolidine iminosugars in future studies.

Indexed as

Imino SugarsEnzyme InhibitorsGlycoside HydrolasesPyrrolidinesEnzyme InhibitorsGlycoside HydrolasesImino SugarspyrrolidinePyrrolidinesglucosidase inhibitorsiminosugarmultivalent effectpyrrolidine

Identifiers

PMID36080188
PMCPMC9457877
OpenAlexW4293221267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.